Oxford Bioscience Partners

Oxford Bioscience Partners

Xconomy

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

the home of AI info

Amgen puts its foot down in shiny new South San Francisco hub as it reorganizes R&D ops

the home of AI info

Amgen to Cut Another 172 Jobs Following Layoff Announcement Earlier This Month

the home of AI info

Amgen chops 172 more staffers in R&D, operations and sales amid neuroscience exit, revenue ...

the home of AI info

Amgen plans to eliminate another 172 jobs

the home of AI info

Amgen cutting almost 150 jobs in Cambridge

the home of AI info

Amgen Ends Neuroscience Research, Cuts Staff in Cambridge

the home of AI info

Drugmaker Amgen cuts a quarter of its Kendall Square research staff

the home of AI info

Amgen And Neuroscience

DealStreetAsia

Amgen to pick up 20.5% stake in BeiGene to expand in China

the home of AI info

Amgen exits neuroscience research, cuts 180 US jobs

the home of AI info

Amgen Exits Neuroscience Research: The Good, Bad, And Ugly Of Biopharma

the home of AI info

Amgen joins neuroscience exodus

the home of AI info

Amgen and Neuroscience

Xconomy , MedCity News

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

the home of AI info

Amgen exits neuroscience R&D to focus on growth areas

the home of AI info

Amgen exits neuroscience R&D as pharma pulls back from field

the home of AI info

Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D

the home of AI info

Amgen is joining the biopharma exodus out of neurosciences R&D

BetaKit

TIAP partners with Amgen to commercialize medical research